Recon: Novavax plans 2B Nuvaxovid doses this year; Biden keys in on Medicare drug prices in State of the Union

• Novavax doubles down on promise to produce 2B Nuvaxovid doses — this year (Endpoints)
• Biden Says ‘Top Priority’ Is Getting Prices Under Control (Bloomberg) (Endpoints) (The Pink Sheet)
• FDA slaps hold on Finch’s C. diff med to get info on COVID-19 screening for donor-derived therapy (Fierce) (Endpoints)
• FDA quickly follows a voluntary pause for CAR-T 2.0 with a clinical hold to investigate 2 patient deaths (Endpoints)
• Pfizer's bacterial infection vaccine fails main goal in study (Reuters)
• NIH orders sweeping review of potentially risky experiments on viruses and other pathogens (The Washington Post)
• How Operation Warp Speed clashed with Pfizer in the early days of the pandemic (Endpoints)
• Progressives Press for More Changes to Medicare Payment Program (Bloomberg)

• EMA Begins Setting Up New Bodies To Tackle Drug Shortages (The Pink Sheet)
• UK Offers To Help ‘Innovation Passport’ Holders Tackle Market Access Challenges (The Pink Sheet)
• Europe's Generics Industry Takes Action To Maintain Medicines Access In Ukraine (The Pink Sheet)
• In Difficult Times For AAV Gene Therapies, AbbVie Boosts Regenxbio’s Ambitions (Scrip)

• Weaker Omicron variant is great news for the world, but bad news for Covid-related clinical trials (Endpoints)
• CDC data suggest Pfizer vaccine protection holds up in kids 5-11, raising questions on earlier study (STAT)
• Nerve damage may explain some cases of long COVID -U.S. study (Reuters)
• White House unveils new plan to move America past covid crisis, says shutdowns, school closures no longer necessary (Washington Post)
• Pfizer to provide 10 mln courses of COVID pill to developing countries -the Global Fund (Reuters) 

• Pfizer joins Sanofi on the C. difficile failure train after its vaccine flopped a PhIII study (Endpoints)
• Sanofi enlists Adagene and its 'masking' tech to develop new I/O drugs, in a deal potentially worth $2.5B (Endpoints)
• 3 burning questions spurred by the big CRISPR patent ruling (STAT) (Biopharma Dive)
• The Family Dollar Inspection Report: How Not To Handle A Rodent Problem (The Pink Sheet)
• As GSK is forced to slam the brakes, Pfizer cruises ahead with a ‘breakthrough’ on RSV (Endpoints)
• Vesalius Therapeutics launches to develop treatments for common diseases (STAT)
• That bullish stance Karyopharm took on its subgroup cancer study data? The FDA wasn't impressed (Endpoints)
• Flagship's latest boast? A startup that will 'revolutionize treatment' for 'ninety percent of human illness' (Endpoints)
• SEC jumps into the FibroGen fiasco with a subpoena, probing cardio data manipulation (Endpoints)

• IVD Expert Panel: First 15 Reviews Performed With Many Requests For Additional Information (MedTech Insight)
• FDA approves J&J’s allergy-fighting contact lens infused with an antihistamine (Fierce)
• QMSR Quick Take: Medtech Consultant Steve Silverman (MedTech Insight)
• FDA Warns Against Use Of 3 Unapproved COVID-19 Tests (MedTech Insight)
• Sanofi strikes $30M strategic agreement with digital health company DarioHealth (MedTech Dive)
• Quanterix links up with Eli Lilly for Alzheimer’s blood biomarker testing collaboration (Endpoints)
• Zimmer Biomet completes spinoff of ZimVie spine, dental business (Fierce)

• Tennessee judge sanctions Endo for withholding opioid documents, refuses to recuse himself from case (STAT)
• Purdue Pharma mediator extends talks to resolve Sackler liability for opioid epidemic  (Reuters)
• 3 Product Liability Highlights from The State of The Union (Law360)
• High Court Poised to Make DOJ's Job Harder in Opioid Cases (Law360)
• Supreme Court debates exactly when a doctor’s misprescribing becomes criminal (STAT)